Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer
ConclusionThe provision of genetic testing to high-risk women with a BRCA1 and two mutation probability of ≥ 10% based on the individual family cancer history appears to be a cost-effective option for the SHI.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Economics | Genetics | Germany Health | Health Insurance | Health Management | Insurance | Mastectomy | Ovarian Cancer | Ovaries | Study | Women